Download Free Breakthrough Therapies Book in PDF and EPUB Free Download. You can read online Breakthrough Therapies and write the review.

More people are in psychotherapy than ever before. Yet most of them have no idea of the vast differences between the hundreds of various schools of therapy. Therapy Breakthrough is the first book to clearly explain the theories and practices of the two big camps: Psychodynamic or PD therapy and Cognitive-Behavioral or CB therapy. PD therapists believe that emotional problems are caused by hidden forces in our unconscious minds, forces that cannot be observed directly and that resist being uncovered. CB therapists, by contrast, maintain that the roots of people’s emotional and behavioral disturbances can be identified by direct questions, and these problems can then be tackled by straightforward techniques. Therapy Breakthrough is written from the standpoint of CB therapy. Using psychological research, philosophy, and common sense, it argues that PD therapy is founded on mistaken theories of the mind, and explains how to apply CB methods directly to your own problems.
Discover the essential guide to Eye Movement Desensitization and Reprocessing therapy (EMDR) from its pioneering creator, Francine Shapiro Gain insights into how painful life experiences are physically stored in our brains and how EMDR therapy can bring relief. Learn how EMDR techniques can be used to address trauma-related conditions, PTSD, depression, anxiety, and other experience-based disorders by exploring clinical case studies. Understand why EMDR is hailed as the most important method to emerge in psychotherapy in decades. EMDR is fundamental reading for practicing psychotherapists and anyone interested in understanding trauma, healing processes, and achieving better mental health.
While most people today vaguely realize that the body is a working machine that generates energy, most of us dont understand the way energy flows, where it goes and what it does. Margaret Rogers research with her clients and under medical supervision has validated ancient Oriental techniques and merged them with exciting non-invasive methods using crystals to unblock energy flow in our Five Bodies and to tone and stimulate the Chi energies. Integrating these techniques with hypnotherapy, reflexology and aromatherapy, she has broken through old mindsets to release cellular-neuro-muscular memories that have created illness of the mind, body and spirit. Whether you are a healer or a patient, you need this stimulating and easy-to-follow guide to recovery.
Captain Bunn founded SOAR to develop effective methods for dealing with flight anxiety. Therapists who have found this phobia difficult to treat will find everything they need to give their clients success. Anxious flyers who have “tried everything” to no avail can look forward to joining the nearly 10,000 graduates of the SOAR program who now have the whole world open to them as they fly anxiety free wherever they want. This approach begins by explaining how anxiety, claustrophobia, and panic are caused when noises, motions—or even the thought of flying—trigger excessive stress hormones. Then, to stop this problem, Captain Bunn takes the reader step-by-step through exercises that permanently and automatically control these feelings. He also explains how flying works, why it is safe, and teaches flyers how to strategically plan their flight, choose the right airlines, meet the captain, and so on. Through this program, Captain Bunn has helped thousands overcome their fear of flying. Now his book arms readers with the information they need to control their anxiety and fly comfortably.
Hope and help arrives in this psychiatrist's preview of emerging and breakthrough therapies for treating more severe, treatment-resistant depression. Over 280 million individuals worldwide suffer from depression every year, with many turning to potent antidepressants and drastic lifestyle changes to help manage their condition and improve their quality of life. But what if these methods don’t work? What if, despite all efforts, an individual continues to suffer? Stubborn, treatment-resistant depression dramatically reduces a person’s quality of life while providing them with seemingly few options for relief. Curing Stubborn Depression seeks to not only explain the underlying causes of this pervasive form of depressive disorder, but to shine light on a number of non-traditional treatments, new therapies and clinical developments—including ECT, transcranial magnetic stimulation, bright light therapy, ketamine and more—offering hope to those who feel like they have none. The field of depression treatment is rapidly evolving and constantly changing, meaning it can be difficult to keep up with new therapies and clinical developments. Curing Stubborn Depression delves into these emergent treatments, many of which are transforming how this condition is managed—and offering hope to those who feel like they have none.
Michael S. Okun, M.D. is internationally celebrated as both a neurologist and a leading researcher. He has often been referred to as, "the voice of the Parkinson's disease patient." He was honored at the White House in 2015 as a Champion of Change for Parkinson's disease. He has an international following on the National Parkinson Foundation's Ask the Doctor web-forum and he is a Professor of Neurology at the University of Florida Health Center for Movement Disorders and Neurorestoration. His many books and internet blog posts are brimming with up-to date and extremely practical information. This book is the sequel to his runaway bestseller, Parkinson's Treatment: 10 Secrets to a Happier Life, which was translated into over 20 languages. Dr. Okun is well known for infusing his readers with positivity and optimism. In his latest book he reveals the breakthroughs in Parkinson's disease that will pave the road to meaningful progress. In this book he reviews all of the recent breakthrough ideas and therapies in Parkinson's disease, and he reviews the knowledge gained which is extending far beyond a single drug or stem cell. He paints the broader and more exciting picture and reviews the portfolio of breakthroughs spanning drug, cell, vaccine, device, genetics, care, and behavior. He believes that patients and families with personal investments in Parkinson's disease should be informed and updated about all of these potential breakthrough therapies. This book informs, educates, and will inspire Parkinson's disease patients, family members, as well as health care professionals and scientists. As Dr. Okun points out, we will journey toward better treatments -- and one day a cure.
This handbook is a collection of clinical narratives that underscore the heterogeneous and unpredictable presentation of multiple sclerosis (MS) and give real-world clinical context to recent drug developments. This accessible and concise publication is intended to be used by a wide range of medical professionals, from specialist neurologists to medical trainees with an interest in neurology. An ideal clinical resource, Case Studies in Multiple Sclerosis provides an evidence-based discussion of each case, with an aim to enhance effective diagnosis and treatment of patients with MS and MS-related conditions.
Vaccinate children against deadly pneumococcal disease, or pay for cardiac patients to undergo lifesaving surgery? Cover the costs of dialysis for kidney patients, or channel the money toward preventing the conditions that lead to renal failure in the first place? Policymakers dealing with the realities of limited health care budgets face tough decisions like these regularly. And for many individuals, their personal health care choices are equally stark: paying for medical treatment could push them into poverty. Many low- and middle-income countries now aspire to universal health coverage, where governments ensure that all people have access to the quality health services they need without risk of impoverishment. But for universal health coverage to become reality, the health services offered must be consistent with the funds available—and this implies tough everyday choices for policymakers that could be the difference between life and death for those affected by any given condition or disease. The situation is particularly acute in low- and middle income countries where public spending on health is on the rise but still extremely low, and where demand for expanded services is growing rapidly. What’s In, What’s Out: Designing Benefits for Universal Health Coverage argues that the creation of an explicit health benefits plan—a defined list of services that are and are not available—is an essential element in creating a sustainable system of universal health coverage. With contributions from leading health economists and policy experts, the book considers the many dimensions of governance, institutions, methods, political economy, and ethics that are needed to decide what’s in and what’s out in a way that is fair, evidence-based, and sustainable over time.
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.